Dec 14 (Reuters) - Bluebird bio (BLUE.O) said on Thursday a large insurer had agreed to cover its newly approved sickle cell disease gene therapy, easing some investor worries about resistance ...

Bluebird said it expects to recognize revenue from Lyfgenia by the end of this year as payments don’t begin until a patient is infused. Overall with its three gene therapies—including TDT ...

That means Bluebird's product, which is called Lyfgenia, will be forced to fight for market share from the get-go. Lyfgenia is priced at $3.1 million per dose, and it's curative or near-curative.

Bluebird’s revenue in the fourth quarter came to $7.8 million, bringing its 2023 figure to $29.5 million, with Zynteglo accounting for $16.7 million and Skysona coming in at $12.4 million.